Wildlife

News & Events

We have the know-how you need. BioLabs International is a worldwide corporation manufacturing and distributing products for the healthcare professionals in clinical, life science, and biopharmaceutical markets as well as we serve to consumers who are seeking better well-being.

July 1, 2020, 12:00:00 PM

PPE Provider From BioLabs International To Make Sure No shortage of PPE COVID-19 demand

Despite the globally rising number of coronavirus COVID-19 infections fuelling concern over a shortage of personal protective equipment (PPE), BioLabs International has stepped up to be the one of PPE providers from the United States of America.

Demand for protective gear has shot up 100-fold since the virus began to spread, according to the WHO, which warned about global shortages of PPE as early as February. It called on manufacturers to increase production by 40% to meet the rising global demand of masks, respirators, gloves, gowns and face shields for frontline health workers.

BioLabs International quickly adjusted their product pipelines in order to have capabilities to work OEM manufacturing PPE within a few short months.

"We have capacity to make a lot of things at big rates and we’re going to provide hopefully from PPE products in a very short period of time," CEO Dr. Samson Chen told several local medias.

Those PPE can be supplied across the U.S. so that our healthcare providers could purchase to make available for their healthcare professionals. More than 1.6 million gowns were made from April alone.

For far too long, the United States relied on foreign manufacturing and supply chains for some most important medicines and active pharmaceutical ingredients while placing America's health, safety and national security at risk during emergency like this COVID-19 pandemic situation.

Dr. Samson Chen, said “America needs a reliable source of high quality, domestically manufactured, affordable pharmaceuticals and their key ingredients. This advanced manufacturing capability will significantly fortify our nation's pharmaceutical supply chain for critical medicines, including many required to treat patients hospitalized with COVID-19."

Over 80 percent of APIs and chemical ingredients used in the U.S. to manufacture generics and over-the-counter drugs are produced overseas. Of these, the majority are produced in China and India.

Genomic.jpg

March 31, 2020, 5:00:00 PM

BioLabs International Announces Launch of COVID-19 Nueclie Acid RT-PCR Test Kits

BioLabs International, has stepped to support medical community in testing COVID-19 suspicious individual in the USA and worldwide. BioLabs discovers solutions to combat COVID-19 by launching nucleic acid molecular RT-PCR test kits.

Genomic.jpg

March 30, 2020, 2:00:00 PM

BioLabs International and GeneOne Diagnostics Corporate Partner to Commercialize Molecular Testing Worldwide

• Partnership to leverage GeneOne’s manufacturing capability with BioLabs International’s expertise in
business development to provide broad access to clinical diagnostic laboratories in the US and
Worldwide
• Innovative molecular testing improves clinical accuracy in various infectious diseases.
• Collaboration agreement to response today’s worldwide coronavirus threat in building up COVID-19
nucleic acid testing kit using RT-PCR to accelerate clinical workflows of confirmation testing among
large population


Cleveland, OH, March 30 2020 – BioLabs International announced today that it has entered into a partnership with GeneOne Diagnostics Corporate to broaden the business development and adoption of molecular testing in various infectious diseases. As the understanding of the new virus evolves in nature environment, which could become a worldwide threat potentially transform risk prediction, detection, diagnosis, treatment and monitoring.

This agreement brings together complementary capabilities of each company to broaden global access from North America to other parts of world. GeneOne Diagnostics will develop, manufacture various testing kits and BioLabs International will commercialize molecular tests using RT-PCR technology. BioLabs International will support the development of the claims and regulatory filings, will also go through regulatory approval process.

“As an innovative company in diagnostic arena that helps save and improve lives, BioLabs International is pleased to enter into a partnership agreement with GeneOne Diagnostics to leverage our combined expertise in clinical testing of infectious diseases and molecular diagnostics,” said Samson Chen, CEO of BioLabs International. “This collaboration is uniquely positioned to improve medical value and clinical decision making globally by combining the unique capabilities of the BioLabs International with GeneOne, and will provide more patients with access to GeneOne Diagnostics products in North America. This builds upon our strategy of accelerating clinical diagnostic, streamlining workflows and expanding assay menus to broaden access to clinical data and lower barriers to routine use.”



About BioLabs International LLC
BioLabs International is a worldwide corporation manufacturing and distributing products for the clinical diagnostics, life science, and biopharmaceutical API markets. We are dedicated in providing research and industrial communities innovative, quality tools to aid them in their quest for scientific excellence.

From innovative products research development to manufacturing, BioLabs International maintains the flexibility to partner with you every step of the way. We bring to the table excellent quality products and experience in research and clinical diagnostics products. We commit to continue to introduce innovative new products of the highest quality. As part of a multi-step process towards meeting and exceeding regulatory compliance standards. Our endless effort is to meet ISO and FDA standards in the United States, some of our products are cGMP compliant and under the FDA's Emergency Use of Authorization.
For more information, please visit www.biolabsinternational.com.

All trademarks used or mentioned in this release are protected by law.

Genomic.jpg